Brief: Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic's Solid Tumor Study Of Eli-002
09/01/2024 11:16
Jan 9 (Reuters) - Elicio Therapeutics Inc ELTX.O :
* NATURE MEDICINE PUBLISHES UPDATED PRELIMINARY PHASE 1 DATA
FROM
ELICIO THERAPEUTIC’S AMPLIFY-201 PHASE 1 SOLID TUMOR STUDY OF
ELI-002
* ELICIO THERAPEUTICS INC - PHASE 2 TRIAL OF ELI-002
MONOTHERAPY
IN PANCREATIC DUCTAL ADENOCARCINOMA ("PDAC") PLANNED TO INITIATE
IN EARLY 2024
Source text for Eikon: ID:nGNX9TP6N4
Further company coverage: ELTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Elicio Therapeutics
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Elicio Therapeutics Q2 net loss narrows as R&D expenses fall
Elicio Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
Elicio shares slide after pancreatic cancer vaccine falls short in mid-stage study (updated)